ClinicalTrials.Veeva

Menu

Efficacy and Safety of IQP-VV-102 in Weight Management

InQpharm logo

InQpharm

Status and phase

Completed
Phase 3

Conditions

Overweight
Obesity

Treatments

Dietary Supplement: IQP-VV-102
Other: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT01681069
INQ/009712

Details and patient eligibility

About

Subjects are randomized to either IQP-VV-102 or a matching placebo. Over 12 weeks, the subjects' body weight, body fat and safety parameters are monitored

Enrollment

120 patients

Sex

All

Ages

18 to 60 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Age 18 to 60 years
  • 25 kg/m2 ≤ BMI ≤ 35 kg/m2
  • Written informed consent

Exclusion criteria

  • Known sensitivity to sources of the active ingredients and excipients
  • Pregnancy or nursing
  • Inability to comply with study requirements, e.g. due to language difficulties
  • Participation in another study during the last 30 days of the screening visit

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

120 participants in 2 patient groups, including a placebo group

IQP-VV-102
Active Comparator group
Description:
2 tablets twice a day
Treatment:
Dietary Supplement: IQP-VV-102
Placebo
Placebo Comparator group
Description:
2 tablets twice a day
Treatment:
Other: Placebo

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems